Search Results
Your search for The ASCO Post matches 17812 pages
Showing 11751 - 11800
Elizabeth Ann Mittendorf, MD, PhD, on ASCO-SITC Meeting Highlights: Expert Perspective
Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these presentations will affect clinical practice.
Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers...
2017 Oncology Meetings
MARCH 2017 ASCO Oncology Practice ConferenceMarch 2 • Orlando, FloridaFor more information: www.asco.org/meetings/symposia-conferences/asco-oncology-practice-conference 23rd Annual Blood-Brain Barrier Consortium Meeting March 2-4 • Stevenson, WashingtonFor more information:...
Effect of Sorafenib and Hepatitis Status in Advanced Hepatocellular Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C...
First-in-Class Rovalpituzumab Tesirine in Recurrent Small Cell Lung Cancer
In a phase I study reported in The Lancet Oncology, Charles M. Rudin, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), produced responses in patients with...
Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer
Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...
Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
Kathleen N. Moore, MD, of Stephenson Cancer Center, The University of Oklahoma, and colleagues found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a...
Rucaparib in Relapsed Platinum-Sensitive High-Grade Ovarian Cancer
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Elizabeth M. Swisher, MD, of the University of Washington, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with...
Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors
In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype...
Columbia, NewYork-Presbyterian, and Life Raft Group Form Cancer Research Partnership
Columbia University Medical Center, NewYork-Presbyterian, and the Life Raft Group, a patient advocacy organization specializing in advanced gastrointestinal stromal tumors (GIST), announced that they have entered into a collaborative research project to investigate the efficacy of a novel system...
Expect Questions About Screening and Potential Overdiagnosis
“The big thing that is going to become more and more of an issue, and that you are going to hear a lot more of this year, and in the next several years, is overdiagnosis,” Otis W. Brawley, MD, FACP, Chief Medical Officer of the American Cancer Society, told The ASCO Post in an interview following...
Continued Reduction in Cancer Mortality Requires Increasing Healthy Behaviors and Removing Inequities in Care
Many news reports about the latest cancer statistics released by the American Cancer Society (ACS) have focused on the 25% reduction in cancer mortality since 1991. Several reports quoted ACS Chief Medical Officer Otis W. Brawley, MD, FACP, who said in a statement1 announcing the publication of...
Stephen Gottschalk, MD, Named Chair of BMT and Cell Therapy at St. Jude
Stephen Gottschalk, MD, has been named Chair of the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital in Memphis. In his new position, Dr. Gottschalk will be responsible for management of the Department’s clinical, research, and educational...
Lisa Lange, ANP-BC, AOCN, of Karmanos Cancer Institute, Promoted to Vice President of Clinical Trials Office
Lisa Lange, ANP-BC, AOCN, of the Barbara Ann Karmanos Cancer Institute, has been promoted to Vice President of the Clinical Trials Office. Ms. Lange brings 26 years of experience as a nurse and nurse practitioner, specializing in clinical oncology care and research. She has been with Karmanos for...
Suresh Ramalingam, MD, Elected to the American Society for Clinical Investigation
Suresh Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University and Assistant Dean for Cancer Research at the Emory School of Medicine, has been elected to the American Society for Clinical Investigation. Dr. Ramalingam, who is the Roberto C. Goizueta Distinguished Chair for ...
Harold H. Tara, Jr, MD, Appointed Medical Director of Smilow Care Centers in Connecticut
Harold H. Tara, Jr, MD, has been appointed Medical Director of the Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, Connecticut. Dr. Tara’s leadership will ensure that the centers continue to offer patients the best care available, along with the latest treatment options through...
Results From MONALEESA-2: Are All CDK4/6 Inhibitors Equal?
Hormone receptor–positive breast cancer is the most common subtype of breast cancer, and while endocrine therapy has long been a mainstay of therapy for these patients, treatment resistance ultimately develops. Therefore, better therapeutic approaches are needed. There are some data to suggest...
First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported by The ASCO Post from the recent European Society for Medical Oncology Conference, first-line treatment with ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), resulted in significantly longer progression-free survival vs placebo in women with hormone...
Clinical Trials Actively Recruiting Patients With Gynecologic Cancers
Phase I Study Title: Phase I Study to Determine the Effects of Mesenchymal Stem Cells Secreting Interferon Beta in Patients With Advanced Ovarian Cancer Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: MD Anderson Cancer Center Purpose: To find the...
Researchers Use Cardiomyocytes to Create Index of Cardiotoxicity of Tyrosine Kinase Inhibitors
Researchers at the Stanford University School of Medicine used heart muscle cells made from stem cells to rank commonly used chemotherapy drugs based on their likelihood of causing lasting heart damage in patients. Tyrosine kinase inhibitors can be an effective treatment for many types of cancers, ...
Development of a Voided Urine Assay for Detecting Prostate Cancer Noninvasively
Scientists at the Sidney Kimmel Cancer Center at Thomas Jefferson University have developed a noninvasive technique to detect the presence of prostate cancer cells in patients' urine. The pilot study, led by Mathew L. Thakur, PhD, Director, Laboratories of Radiopharmaceutical Research and Molecular ...
University of Pittsburgh Medical Center Joins International Coalition to Improve Cancer Care
A new global initiative that includes founding partner University of Pittsburgh Medical Center was launched on January 17, 2017, at the World Economic Forum’s Annual Meeting in Davos, Switzerland. It signals a dramatic shift in the way international organizations help country and city leaders...
Regorafenib in Second-Line Setting for Hepatocellular Carcinoma: Balancing Benefit With Toxicity
During the past 40 years, hundreds of randomized trials testing treatments for advanced hepatocellular carcinoma have been published.1 Conventional systemic chemotherapy and radiotherapy lack survival advantages for these patients.1,2 In 2007, a phase III trial demonstrated survival benefits for...
Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bangladesh
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions...
Pittsburgh Cancer Center Researchers to Receive 2017 Paul Ehrlich and Ludwig Darmstaedter Prize
One of the most prestigious awards in the field of medicine will be presented to University of Pittsburgh School of Medicine faculty members and University of Pittsburgh Cancer Institute (UPCI) researchers Yuan Chang, MD, and Patrick S. Moore, MD. The duo, whose Chang-Moore Laboratory at the...
American Cancer Society Awards Medal of Honor to Three Cancer Researchers
Three outstanding individuals have been honored with the American Cancer Society Medal of Honor Award. The Medal of Honor is awarded to those who have made the most valuable contributions and impact in saving more lives from cancer through basic research, clinical research, and cancer control....
Radiotherapy vs Temozolomide in Low-Grade Glioma: The Importance of Molecular Classification
The optimal treatment strategy for low-grade glioma has yet to be established, and practice patterns vary in regard to the timing of treatment, as well as the chosen treatment modality. It was against this backdrop, at a time when the benefits of radiation and chemotherapy remained uncertain but ...
Study Finds Children, Parents Overreport Adherence to Leukemia Treatment
New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in...
Clinical Trial to Explore Genetic Cancer Test to Offer Safe Thyroid-Preserving Surgery
University of Pittsburgh School of Medicine scientists and doctors are embarking on the first-ever clinical trial to determine whether a genetic test they pioneered could successfully spare patients with nonaggressive thyroid cancer from complete removal of their thyroid. Such thyroid-preserving...
$1.8M Grant to Wenwei Hu, PhD, to Aid Exploration of Role of Chronic Stress in Cancer Development
A 5-year, $1.8 million grant from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors—p53. The aim is to explore...
Expert Point of View: Jose Leis, MD, PhD
Jose Leis, MD, PhD, of the Mayo Clinic in Arizona, commented on the promise of checkpoint inhibitors in Richter transformation. “At Mayo, we have treated more than 30 patients with programmed cell death protein 1 (PD-1) blockade. We do see that chronic lymphocytic leukemia (CLL) has low expression ...
American Cancer Society Honors William Breitbart, MD, With the Trish Greene Quality of Life Award
William Breitbart, MD, has been honored with the 2017 American Cancer Society Trish Greene Quality of Life Award, a prestigious national honor that recognizes an outstanding individual who dedicates a significant portion of his or her career to research that improves the quality of life for cancer ...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. The expanded indication makes...
Payers Weigh the Implications of Multigene Testing Coverage
Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component. Additionally, the importance of inherited cancer genomics was further bolstered by former President Barack Obama’s Precision...
Continuing Education Information
This CE/CME/CU-accredited supplement is jointly provided by: To earn credit/contact hours, you must read all the articles in this supplement and then go to https://education.annenberg.net/IASLC Release date: February 25, 2017 Expiration date: February 25, 2018Annenberg Center for Health...
Southern Surgical Association Annual Meeting: Isolated Limb Infusion for Extremity Sarcoma May Preserve Limbs
Patients with advanced malignant soft-tissue sarcoma of the extremities have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these...
More Patients With Early-Stage Breast Cancer May Be Able to Avoid Chemotherapy in the Future
Women with early-stage breast cancer who had an intermediate risk recurrence score from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds. The research, published by Barcenas et al in ...
Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies
Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.
Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations
Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeutic direction the data suggest. (Abstract 149)
Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response
Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)
Sumanta K. Pal, MD, on Advanced Renal Cancer: Treatment Challenges
Sumanta K. Pal, MD, of the City of Hope, summarizes a session he co-chaired on the opportunities and challenges in systemic therapy for advanced renal cancer, including imaging as a biomarker of response and optimal selection of front-line treatments. (General Session 9)
Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)
Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment
Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)
W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition
W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.
Sumanta K. Pal, MD, on RCC and Tumor Profiling
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)
Paul L. Nguyen, MD, on Predicting Metastasis and Mortality
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, discuses an evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic needle biopsy specimens. (Abstract 4)
Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on atezolizumab with or without bevacizumab vs sunitinib in patients with untreated metastatic renal cell carcinoma. (Abstract 431)
Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals
Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.
